Lionheart Health Inc.’s newest partnership is set to increase sales for its platform of regenerative aesthetics and age-reversing products.
Lionheart this month said that it’s partnering with Scottsdale, Ariz.-based ElectroMedical Technologies Inc. (OTC: EMED), which specializes in making bioelectronics for chronic pain.
Lionheart, based in Mission Viejo, will gain access to EMED’s sales reps in all 50 states in the U.S. as part of the deal, according to Lionheart Chief Executive Howard Leonhardt.
“We’re going to collaborate together using their strengths and our strengths to broaden sales,” Leonhardt told the Business Journal.
The partnership will combine Lionheart’s software with EMED’s hardware on future bioelectric products.
The news comes just as EMED prepares to launch its WellnessPro Infinity stimulation device this quarter.
Lionheart, founded in 2021, so far has raised $3 million to date from its parent company and startup accelerator Leonhardt Ventures, also founded by Leonhardt.
Age Reversal
Lionheart’s mission is to reverse aging 10 years or more using its regenerative technologies.
“We hope to make 80 the new 60, so to speak,” Leonhardt said.
Lionheart has over 40 patents for “protein expressions” to heal and regenerate tissue, muscles, nerves and blood vessels.
“I don’t know of any other group or company today that has such a large patent portfolio,” Matthew Wolfson, CEO of EMED, told the Business Journal. “Our goal this quarter is to release the WellnessPro Infinity to market with the strategic partnership with Lionheart Health to enhance the value of our stock to our shareholders.”
The WellnessPro Infinity is a compact device that allows patients to continue their therapy at home, Wolfson said. After electrodes are placed on areas on the body experiencing chronic pain, patients choose from a setting in the device’s menu to start the electrotherapy.
Lionheart will also sponsor clinical trials in brain health, joint health, sexual health and skin and hair rejuvenation as part of its collaboration with EMED, which currently counts a market cap of less than $1 million.
IPO Plans
Leonhardt disclosed plans to file an initial public offering for Lionheart Health either in late 2025 or 2026.
Lionheart will invite its key suppliers and partners, including EMED, to become a part of Lionheart via a roll-up acquisition before the IPO, Leonhardt said.
It wouldn’t be the first time Leonhardt took a company public.
Prior to Lionheart, he founded Sunrise, Fla.-based biotechnology company BioHeart Inc. in 1999, which went public in 2008 and was the only biotech IPO in the U.S. that year amid the 2008 financial crisis.
BioHeart raised $5.8 million from the IPO, offering 1.1 million shares at $5.25 per share, significantly below its initial goal of $57 million.
Leonhardt is no longer involved with BioHeart after resigning in 2013 to “pursue other business matters,” according to a news release. The company since changed its name to U.S. Stem Cell Inc.
Medspa Openings
Lionheart also plans to open 124 total medspas over the next five years and said it is currently ahead of schedule.
Lionheart is on track to open its first six medspas in New York, Newport Beach, San Diego, Beverly Hills, Scottsdale and London within the next month, according to Leonhardt.
All locations will offer EMED’s line of Infinity technologies.
Lionheart is expected to hold an upcoming grand opening for its Newport Beach location on June 21, Leonhardt said.
